Bristol-Myers Squibb: Oncology Franchise Remains A Core Strength

Group 1 - Bristol-Myers Squibb Company (BMY) shares have increased by 27.7% since mid-November, outperforming the S&P 500, which returned 3.6% during the same period [1] Group 2 - Allka Research has over two decades of experience in investment, focusing on uncovering undervalued assets in various sectors including ETFs, commodities, technology, and pharmaceuticals [2] - The firm emphasizes a conservative investment approach, aiming to deliver substantial returns and strategic insights to clients [2] - Allka Research seeks to simplify investment strategies for both seasoned and novice investors, fostering a community of informed investors [2]